Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Favipiravir for Severe Fever with Thrombocytopenia Syndrome (Historical Control)
jRCT2080223816Phase 3Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of favipiravir in severe fever with thrombocytopenia syndrome (SFTS), sponsored by FUJIFILM Toyama Chemical. Started Feb 2018; status: completed.
02
Drugs
favipiravir
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on jRCT2080223816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223816.